Pliant Therapeutics (PLRX) announced the appointment of Minnie Kuo as Chief Development Officer. Kuo will oversee all aspects of the Company’s nonclinical and clinical development activities. Prior to joining Pliant, Kuo held roles of increasing responsibilities at Vir Biotechnology (VIR), most recently serving as Senior Vice President of Translational and Clinical Development Operations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PLRX:
- Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
- Pliant Therapeutics management to meet with Oppenheimer
- Pliant Therapeutics price target lowered to $54 from $57 at RBC Capital
- Pliant Therapeutics reports Q2 EPS (70c), consensus (71c)